Answers are grounded in this paper and cite their sources.
Investigates cytokine responses post-TBI, highlighting celastrol's immunomodulatory effects.
Traumatic brain injury (TBI) involves a transition from acute to chronic neuroinflammation that contributes to lasting neurological deficits; however, the mechanisms by which brain-derived inflammation orchestrates brain-periphery interactions and how to modulate them remain incompletely understood. This multi-compartment study assessed cytokine concentrations across paired serum, cerebrospinal fluid, and ipsilateral hippocampal lysate samples 48 h after controlled cortical impact. Celastrol, an understudied anti-inflammatory compound in TBI, was used as a model therapeutic to evaluate the utility of multi-compartment sampling in pre-clinical therapy screening. Multi-compartment factor analysis (MCFA) was applied as a novel machine learning workflow to identify covariance patterns across fluid and tissue TBI biomarkers. Injury-induced responses were greatest in the hippocampus (IL-6, KC/GRO, and tumor necrosis factor-alpha [TNF-α] increases), with serum decreases in IL-6 and TNF-α. Celastrol restored serum TNF-α to control levels. Sensitivity analyses after outlier removal additionally revealed hippocampal IFN-γ suppression, CSF IL-1β and TNF-α elevation, and celastrol-associated increases in hippocampal IL-10 and IFN-γ. MCFA uncovered coordinated CSF shifts in IL-6, IL-1β, and KC/GRO not individually significant by standard methods and identified a serum inflammatory pattern tracking hippocampal inflammation. Cross-compartment correlations were limited, supporting local regulation. Multivariate dispersion analysis revealed that untreated injury doubled inter-animal inflammatory heterogeneity across the factor space, while celastrol restored dispersion to sham-like levels, indicating treatment re-consolidated the multi-compartment inflammatory response. These findings demonstrate a compartment-specific inflammatory response 48 h post-TBI and suggest celastrol exerts cytokine- and compartment-specific immunomodulatory effects. MCFA provided insights beyond traditional analyses and a standardizable framework for characterizing serum signatures of active brain injury with translational potential for broader TBI biomarker datasets.
No takes yet. Share an insight, caveat, or question.
Gjesdal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: